首页> 外文期刊>Journal of Pharmacy and Pharmacology >Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima Fatty rat: a model of human type 2 diabetes mellitus.
【24h】

Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima Fatty rat: a model of human type 2 diabetes mellitus.

机译:中国处方八神味甘抗大冢长埃文斯德岛肥胖大鼠的肾脏损害:人类2型糖尿病模型。

获取原文
获取原文并翻译 | 示例
           

摘要

Currently, in Japan, approximately 95% of patients with diabetes mellitus have non-insulin-dependent (type 2) diabetes mellitus (NIDDM), and diabetic nephropathy is a major cause of patients requiring chronic haemodialysis. A previous study showed that Hachimi-jio-gan has a protective effect in rats subjected to subtotal nephrectomy plus streptozotocin injection, a model of insulin-dependent (type 1) diabetic nephropathy. In this study, we used the Otsuka Long-Evans Tokushima Fatty (OLETF) rat, a model of human NIDDM, to investigate whether long-term administration of Hachimi-jio-gan affects glycaemic control and renal function in NIDDM. Male OLETF rats, aged 22 weeks, were divided into 4 groups of 10 and given Hachimi-jio-gan (50, 100 or 200 mg kg(-1) daily) orally or no treatment for 32 weeks. Male Long-Evans Tokushima Otsuka (LETO) rats (n = 6) were used as non-diabetic normal controls. Hachimi-jio-gan reduced hyperglycaemia dose-dependently from 16 weeks of the administration period. Urinary protein excretion decreased significantly from an early stage, and creatinine clearance levels improved at 32 weeks. In addition, the levels of serum glycosylated protein and renal advanced glycation end-products were effectively reduced. Hachimi-jio-gan also significantly reduced the levels of thiobarbituric acid-reactive substances in renal mitochondria, although it showed only a tendency to reduce these in serum. Furthermore, long-term administration of Hachimi-jio-gan reduced renal cortical expression of proteins, such as transforming growth factor-beta1 (TGF-beta1), fibronectin, inducible nitric oxide synthase and cyclooxygenase-2. The 100- and 200-mg kg(-1) daily doses of Hachimi-jio-gan significantly reduced TGF-beta1 and fibronectin protein expression to levels below those of LETO rats. These data suggest that Hachimi-jio-gan may have a beneficial effect on the progression of diabetic nephropathy in OLETF rats by attenuating glucose toxicity and renal damage.
机译:当前,在日本,大约95%的糖尿病患者患有非胰岛素依赖型(2型)糖尿病(NIDDM),而糖尿病肾病是需要进行长期血液透析的患者的主要原因。先前的一项研究表明,八神ji干对全肾切除术和链脲佐菌素注射(一种胰岛素依赖型(1型)糖尿病肾病的模型)大鼠具有保护作用。在这项研究中,我们使用了大冢长埃文斯德岛肥胖(OLETF)大鼠(一种人类NIDDM模型)来研究长期服用Hachimi-Jio-gan是否会影响NIDDM的血糖控制和肾功能。将雄性OLETF大鼠(22周龄)分为4组,每组10只,并口服或口服未经治疗的Hachimi-ji-gan(每天50、100或200 mg kg(-1))32周。雄性长埃文斯德岛大冢(LETO)大鼠(n = 6)被用作非糖尿病正常对照。 Hachimi-jio-gan从给药期的16周开始剂量依赖性地降低高血糖症。尿蛋白排泄从早期开始显着减少,并且肌酐清除率水平在32周时有所改善。此外,有效降低了血清糖基化蛋白和肾脏晚期糖基化终产物的水平。 Hachimi-jio-gan还显着降低了肾脏线粒体中的硫代巴比妥酸反应性物质的水平,尽管仅显示出降低血清中这些物质的趋势。此外,长期服用八味椒甘还可以减少肾皮质蛋白质的表达,例如转化生长因子-beta1(TGF-beta1),纤连蛋白,诱导型一氧化氮合酶和环氧合酶-2。每天100和200 mg kg(-1)的Hachimi-Jio-gan剂量可将TGF-β1和纤连蛋白的蛋白表达水平明显降低至LETO大鼠以下。这些数据表明Hachimi-jio-gan可能通过减弱葡萄糖毒性和肾脏损害,对OLETF大鼠糖尿病性肾病的进展具有有益作用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号